Tafnat is an antiviral medication used for the treatment of chronic hepatitis B virus infection. It contains tenofovir alafenamide, a newer generation of tenofovir designed to be more targeted in its action and less toxic to the kidneys and bones. Tafnat is taken once daily and is suitable for long-term use, offering a safer and more effective option for managing hepatitis B.

Mechanism of Action:
Tafnat works by stopping the hepatitis B virus from multiplying inside the body:

• Tenofovir alafenamide is a prodrug, meaning it becomes active only after being absorbed and processed inside liver cells.

• Once activated, it is converted into tenofovir diphosphate, which blocks the virus’s reverse transcriptase enzyme.

• This enzyme is crucial for the virus to make copies of its genetic material. By blocking it, Tafnat helps stop the virus from spreading further in the liver.

  Uses:
  Tafnat is used for:

  • The treatment of chronic hepatitis B infection in adults and adolescents aged twelve years and above with signs of active viral replication or liver inflammation.

  • Its goal is to suppress the virus, reduce liver inflammation, and prevent complications like cirrhosis or liver cancer.

    Adverse Effects:
    Tafnat is generally well tolerated, with a lower risk of kidney and bone-related side effects compared to older forms of tenofovir. However, some individuals may experience:

    • Headache

    • Nausea

    • Tiredness

    • Stomach discomfort